Collaboration with global pharmaceutical partner

• Collaboration will leverage ArestatTM to develop a novel formulation of partner's proprietary product with enhanced properties
• Work will be fully funded by partner

Cambridge, UK, 26 March 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has signed a formulation study agreement with a major global pharmaceutical partner.

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel formulation of the partner's proprietary product with enhanced properties. The partner company will fully fund the formulation work with the potential for future license opportunities to follow.

Sarah Howell, Chief Executive Officer of Arecor, said: "Arecor continues to partner with the world's leading pharmaceutical companies, which is testament to our leadership position in the field of drug delivery and formulation innovation and further validates the potential of our proprietary technology platform, Arestat™ to enable enhanced formulations of partners' proprietary products which would otherwise be unachievable."

This announcement contains inside information for the purposes of the retained UK version of the

EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").